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The MLL/SET family and haematopoiesis☆
Eric T.B. Antunes, Katrin Ottersbach⁎
MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, Scotland, UK
A B S T R A C T
As demonstrated through early work in Drosophila, members of the MLL/SET family play essential roles during embryonic development through their participation
in large protein complexes that are central to epigenetic regulation of gene expression. One of its members, MLL1, has additionally received a lot of attention as it is a
potent oncogenic driver in different types of leukaemia when aberrantly fused to a large variety of partners as a result of chromosomal translocations. Its exclusive
association with cancers of the haematopoietic system has prompted a large number of investigations into the role of MLL/SET proteins in haematopoiesis, a
summary of which was attempted in this review. Interestingly, MLL-rearranged leukaemias are particularly prominent in infant and paediatric leukaemia, which
commonly initiate in utero. This, together with the known function of MLL/SET proteins in embryonic development, has focussed research efforts in recent years on
understanding the role of this protein family in developmental haematopoiesis and how this may be subverted by MLL oncofusions in infant leukaemia. A detailed
understanding of these prenatal events is essential for the development of new treatments that improve the survival specifically of this very young patient group.
1. Introduction
Within a vertebrate embryo, blood development occurs at different
anatomical sites through a series of transient events (reviewed in [1]).
In mouse and before the onset of circulation, a primitive wave of
megakaryocytes, macrophages and nucleated erythrocytes is generated
in the extra-embryonic yolk sac starting from E7.5 (16–18.5 days post
conception in human), and serves the initial oxygen and tissue re-
quirements in the embryo [2,3]. A second extra-embryonic wave, de-
finitive in nature, starting at E8.25 generates erythro-myeloid pro-
genitors (EMPs) and immune-restricted progenitors within a functional
vascular system [4,5]. The definitive route to a functional adult blood
system is initiated at E10.5 within the intra-embryonic aorta-gonads-
mesonephros (AGM) region [6–8]. This generates the first multipotent
haematopoietic stem cells (HSCs) that are defined by their capacity to
self-renew and provide multilineage haematopoietic reconstitution
upon direct transplantation. Following this, blood progenitors circulate
and seed the foetal liver from E11, where the system proliferates and
differentiates further to establish an adult-type haematopoietic hier-
archy apparent from E12.5 (Fig. 1), before colonising the bone marrow
from E18, as the main haematopoietic site throughout adulthood [1].
For haematopoiesis, HSCs must differentiate and enter the cell cycle
to begin the production of the blood lineages through the sequential
generation and lineage-restriction of intermediate progenitor cells that
possess multipotent and unipotent capacities. This hierarchical range of
lineage potency allows for the dynamic usage of HSCs and multipotent
progenitors (MPPs) for the maintenance and regeneration of blood
during native or stressed conditions. Although far from complete,
single-cell and lineage-tracing technologies are increasingly resolving
the cellular heterogeneity within the classically defined haematopoietic
stem and progenitor (HSPC) populations. The view that haematopoiesis
occurs within an absolute hierarchical framework governed by discrete
transitions through increasingly restricted progenitors is being chal-
lenged, towards a framework where there is a continuous landscape of
differentiation towards the terminal lineages that emerges from tran-
sitionary low-primed HSPC states (reviewed in [9]).
Given the requirement for dynamic functionality, chromatin is sui-
tably poised as an amenable platform to dictate blood function. At the
nucleosome – the basic subunit of chromatin – approximately 146 base
pairs of double-stranded DNA is wrapped around an octamer of histone
proteins. Given that nucleosomes are innately inhibitory to transcrip-
tion, nucleosomal modification or displacement is required to allow for
gene expression [10,11]. This can be achieved through the action of
multi-domain proteins that respond to intrinsic and extrinsic cellular
signals to modify histones or assemble in multi-protein complexes and
configure chromatin interactions and structure, thereby facilitating cell-
specific gene expression.
In mammals, a family of six methyltransferases that can mono-, di-
or tri-methylate histone 3 on lysine 4 (H3K4) through a highly con-
served catalytic Su(var)3–9, Ezh2, Trithorax (SET) domain have be-
come notable for their role in blood function, cancer and development
[12–14]. Known as the mixed-lineage leukaemia (MLL)/SET or
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COMPASS family, the shared catalytic domain was first purified and
characterised as a multi-protein complex in yeast S. cerevisiae as SET1,
where it is entirely responsible for H3K4 methylation [15–19]. This
singular yeast enzyme shares homology with three proteins in D. mel-
anogaster known as SET1, Trithorax (Trx) and Trithorax-related (Trr),
also responsible for H3K4 methylation [20–25]. Seminal work in the fly
showed that Trx, a part of the Trithorax protein group (TrxG), main-
tains initiated patterns of HOX gene expression that function to specify
body segment identity [20,25–27]. TrxG antagonise the repressive ac-
tion of the Polycomb protein group (PcG), allowing both systems to
control these transcriptional states over successive cell divisions during
morphogenesis [20,28,29].
The six MLL/SET paralogs in vertebrates likely reflect a historical
duplication event of ancestral SET genes [30]. The family can be split
into pairs: MLL1/MLL2 (KMT2A/B), MLL3/MLL4 (KMT2C/D) and
SETD1A/SETD1B (KMT2F/G) based on sequence conservation, which
suggests that SET containing proteins have diverged to acquire further
and distinct functionalities beyond enzymatic function [14]. Much has
been well documented about the history of discovery, structure and
distinct functions of S. cerevisiae SET1, the D. melanogaster SET family
and the mammalian MLL/SET proteins in development and disease
[13,14,20,30]. This review will aim to describe how the MLL/SET fa-
mily contribute to haematopoiesis, whilst drawing relevant information
from studies of MLL1-associated leukaemia and development, where
much work has been conducted.
2. A short guide to the structures and interactions of the MLL/SET
family
The MLL/SET family commonly share a minimal core complex re-
quired for proper histone methyltransferase (HMT) activity that con-
sists of the WD-40 repeat-containing protein 5 (WRD5),
Retinoblastoma-binding protein 5 (RBBP5), absent, small, or homeotic-
like (Drosophila) (ASH2L) and Dumpy-30 (DPY30) (WRAD) [31–35].
By building on the repertoire of possible binding modes that recon-
stituted mammalian MLL/SET and yeast COMPASS utilise when
binding the nucleosome, high-resolution structural data are beginning
to demonstrate how the WRAD scaffold functions to coordinate the
activation of the SET domain [36–40]. Nucleosomal specificity and
catalytic activation is mediated through an initial contact with a
monoubiquitinated histone at lysine 120 (H2BK120ub1) which sets in
motion a cascade of events within the catalytic module and towards the
nucleosome, that allosterically prime the SET domain to sequester the
N-terminal tail of H3 for subsequent methylation [36,40–42]. Sub-
stitution of a series of residues from MLL1 that connects WRAD to the
MLL1 SET domain markedly increased MLL3 activity, by allowing the
MLL3 chimera to assume a catalytic conformation more like MLL1,
which negated the repressive action of WRD5 usually seen in the native
MLL3 complex [36]. The catalytic efficiency of both mammalian MLL1/
3 and yeast COMPASS are markedly reduced when binding an un-
modified nucleosome [36,41]. Thus, H2BK120ub1 indirectly simulates
enzymatic activity, and differences in inter-subunit structure contribute
to the varying affinities within the MLL/SET family for HMT potential.
Whilst they all share a relatively small SET domain, all MLL/SET
members contain unique combinations of structural domains, with
domain usage being closely shared between their respective pairs
(Fig. 2). The WRAD complex also serves as a platform for the recruit-
ment of interaction partners that further multi-domain functionality.
Trx-like MLL1 and MLL2 are both cleaved by Taspase 1 [43]. For MLL1,
this generates 320 kDa N-terminal and 180 kDa C-terminal fragments,
which non-covalently dimerise via FYRN and FYRC domains to form the
first hub for multi-protein complex assembly [44–47]. Both retain all
chromatin and protein interaction functionality at the N-terminal
fragment, and catalytic SET function at the C-terminus (Fig. 2). Further
contributors to MLL1 and MLL2 function are unique interactions with
menin and, specific to MLL1, the formation of a ternary complex with
the lens epithelium-derived growth factor (LEDGF) [48–53]. Further-
more, MLL1 co-localises with transcriptionally activating lysine
Fig. 1. Developmental haematopoiesis.
Depicted are key stages in the development of the haematopoietic system during mouse embryogenesis and how they can be differentially targeted with tissue-
specific Cre recombinases. The first blood cells are generated in the E7.5 yolk sac in blood islands highlighted in red. A day later, the yolk sac gives rise to the first
definitive haematopoietic progenitors, erythro-myeloid progenitors (EMPs) and their counterparts, immune-restricted progenitors. The first adult-type haemato-
poietic stem cells (HSCs) appear in the intra-embryonic aorta-gonads-mesonephros region, located between the forelimbs and hindlimbs of the E10.5 embryo as
shown. HSC expansion and the establishment of an adult-type haematopoietic hierarchy occurs in the foetal liver (FL) from E12.5, thus making it the most important
haematopoietic organ from midgestation.
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acetyltransferases and PAF1, indicating an ability to associate with
different factors to target specific functions [54–58]. Thus far, only
MLL2 interacts with AKAP95 [59]. Trr-like MLL3 and MLL4 do not bind
to menin or LEDGF, but specifically interact with p53, UTX, PA1, PTIP
and NCOA6 (Fig. 2) [60–64]. Structurally, both SETD1A and SETD1B
are highly similar and share the interaction partners CFP1 and WDR82
(Fig. 2) [65,66]. Both lack a CXXC domain found in MLL1 and MLL2,
and exploit its presence in CFP1 to target activity to gene promoters
[67,68]. WDR82 forms a link to the C-terminal phosphorylated serine 5
on RNA polymerase II at actively transcribing genes [69,70]. For fur-
ther reading there is extensive and excellent literature on the full
spectrum of shared and unique interacting partners for MLL/SET pro-
teins [14,71].
3. MLL1 is required for foetal and adult blood
The first indication that MLL1 may be required in haematopoiesis
came from its identification in chromosomal translocations of in-
tractable mixed-lineage infant leukaemias. Subsequent sequencing by
independent groups revealed that MLL1 was functionally orthologous
to Trx in Drosophila [27,72–74]. Given that it was known that Trx
functions as a homeotic gene regulator during embryonic development,
this set the framework for a series of mouse germline knockout ex-
periments aimed at understanding how Mll1 functions in mammalian
cells.
All Mll1 mutants presented with shifted anterior-posterior body
axes, owing to Mll1 failing to maintain initiated Hox gene expression
patterns from E8.5 [75,76]. This showed that Mll1 is essential for
proper axial skeleton formation in the embryo and confirmed the
functional conservation between Mll1 and Trx. Haematopoietic defects
were most prominent in null embryos, which were lethal from E10.5 to
E16.5 owing to differences in gene targeting [76–79]. Homozygous
mutants were characterised by reduced cellularity in the foetal liver and
reduced myeloid colony forming units (CFU) derived from either the
yolk sac at E10.5 or foetal liver at E12.5. Mll1−/− HSPCs still differ-
entiate but later as compared to wild-type cells, with no abnormalities
in lineage distribution across all genotypes. Thus, the reduction in total
output and delayed onset of proliferation indicates that Mll1 acts to
mediate the generation of HSPCs and not maturation. Gene expression
analyses showed that Mll1 loss is linked to reduced expression of
Hoxa7/8/10 in the foetal liver [78]. Despite HSPC loss in Mll1−/−
embryos, those that do remain can support an expansion of Ter119+
erythroid cells between E13.5-E14.5 and, phenotypically, the embryos
appear to be able to support erythropoiesis [79]. In contrast, hetero-
zygosity causes a mild anaemia and shifts HOX gene expression pos-
teriorly as compared to total loss in Mll1−/−. Haploinsufficient em-
bryos also present with anaemia, thrombocytopenia and reduced
numbers of B-lymphocytes and CFU, indicating that MLL gene dosage is
critical to blood development and may also be relevant in MLL1-rear-
ranged leukaemia, as only one wild-type allele remains when the other
one is involved in a chromosomal translocation [76–78]. In line with
previous results, Mll1 null embryonic stem cells (ESCs) are unable to
generate lymphoid or myeloid progeny in the foetal liver of chimeric
mice [80]. Injection of dissociated E11.5 whole AGM tissue into sub-
lethally irradiated recipients revealed an absence of donor contribution
from Mll1−/− embryos, and very low-level reconstitution from het-
erozygotes, confirming that Mll1 is required for the first functional
HSCs [80]. These findings showed that Mll1 is essential for the speci-
fication of functional HSPCs during embryogenesis and that hap-
loinsufficiency has a pathological role.
Fig. 2. MLL/SET family domain structure and interactions.
This representation shows the basic domain structure and protein interactome for all six MLL/SET family proteins. At the C-terminus, all commonly share an
interaction with the WRAD scaffold that coordinates the activation of the catalytic SET domain, responsible for H3K4 methylation. Different domains between and
within MLL/SET pairs are responsible for protein and DNA interactions. The numbers indicate the length in amino acids of the protein sequences. AT-hooks,
adenosine-thymidine-hook; CXXC, Zinc finger-CXXC domain; FYRN/C, phenylalanine and tyrosine rich region (N- and C-terminal); HMG, high mobility group; RRM,
RNA recognition motive; PHD, plant homeodomain; SET, Su(var)3–9, Ezh2, Trithorax; CFP1, CXXC finger protein 1; LEDGF, lens epithelium-derived growth factor;
NCOA6, Nuclear Receptor Coactivator 6; PA1, PAXIP1-associated glutamate-rich protein 1; PTIP, PAX transcription activation domain interacting protein; NCOA6,
Nuclear receptor coactivator 6; UTX, lysine-specific demethylase 6A; WDR82, WD repeat-containing protein 82; WRAD, WD-40 repeat-containing protein 5, RBB5,
Retinoblastoma-binding protein5, ASH2L (Absent, Small, Or Homeotic)-Like (Drosophila) and DPY30, Dumpy-30.
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As opposed to global deletion, blood-specific inducible knockout
systems of Mll1 deletion were developed and revealed a loss of severity
in observed phenotype, likely as a consequence of losing intrinsic Mll1
function alone [79,81,82]. During foetal development, constitutive
haematopoietic-specific Mll1 deletion with Vav-Cre showed no changes
in the HSPC numbers between E13.5 - E15.5 or differences in blood
lineage distribution, which contrasts with the germline knockouts
[79,82]. Yet, Mll1−/− foetal HSPCs survive to birth, which is shortly
followed by catastrophic bone marrow failure within 3 weeks [82].
Indeed, Vav-Cre-deleted Mll1−/− foetal HSPCs have functionally de-
fective CFU output and are unable to reconstitute irradiated adult re-
cipients in competitive transplants. Therefore, during embryonic de-
velopment, Mll1 is intrinsically required for the specification of
transplantable HSCs and plays a part in HSPC differentiation (Table 1).
The loss of severity in the conditional knockouts could result from ex-
ternal support mechanisms that do not function in the germline mu-
tants.
During adult haematopoiesis, acute Mx1-Cre Mll1 deletion fol-
lowing polyinosinic:polycytidylic acid administration leads to rapid
bone marrow failure within 3 weeks as demonstrated by an overall loss
in cellularity and widespread depletion of the HSPC compartments
[81]. Less penetrant Mll1 alleles in Vav-Cre mice showed that the B-cell
and not T-cell development was especially susceptible to the loss of
Mll1. All models demonstrated a specific loss in total number of HSPCs,
defective CFU output in both myeloid and lymphoid conditions, and a
total loss of engraftment capacity [79,81,82]. Mechanistically, Mll1 loss
caused a failure to maintain quiescence in HSCs, which depleted the
pool. Excision of Mll1 via retroviral induction of Cre in adult myeloid-
erythroid progenitors resulted in a two-fold reduction in CFU. Fur-
thermore, mutant myeloid-erythroid progenitors were not able to re-
enter the cell cycle following the re-addition of cytokines. Therefore,
Mll1 is required during adult haematopoiesis to maintain functional
HSCs through quiescence and it sustains cytokine-mediated prolifera-
tion of at least myeloid-erythroid progenitors.
3.1. Mll1 and B-cell development
Initially, there were conflicting reports for the requirement of Mll1
in the B-cell compartment. Vav-Cre-deleted Mll1−/− mice displayed
reductions in the numbers of B-cells, much more than T-cells [82].
However, as bone marrow failure was significant, this may have im-
paired B-cell output more than T-cell output. Contrastingly, CD19-Cre
mediated Mll1 deletion in adult mice showed no change in B-cell
numbers [81]. To circumvent the previously lethal bone marrow phe-
notype, Rag1-Cre (targeting B and T lymphocytes) mice were crossed
with Mll1 floxed animals, which mediates deletion from late gestation
to adulthood [83]. Significant losses in B-cell numbers were seen in
both foetal and adult mice, in the bone marrow, spleen, blood and
lymph nodes and highest between 2 and 3 weeks. T-cell numbers re-
mained unaffected. Mll1 deficiency impaired B-cell differentiation at
the pre-BCR checkpoint, thus blocking the transition from pro-B to pre-
B resulting in reduced survival. This was attributed to attenuated RAS-
MEK-ERK signalling downstream of the pre-BCR causing reduced
ERK1/2 phosphorylation. Further implicated was a network of various
mRNAs and microRNAs, and no single candidate gene could explain the
observed phenotype, suggesting that these RNA candidates act between
Mll1 and RAS-MEK-ERK signalling. Further insight into Mll1 function
during normal B-cell development has been derived from the analysis of
MLL-AF4 patient data, where an increased MLL1 and BCL6 expression
signature was identified [84]. Virally induced Cre-mediated deletion of
Mll1 in murine pre-B and mature splenic B-cells resulted in a loss of
Bcl6 upregulation from 2 weeks. Interestingly, doxycycline-mediated
induction of Bcl6 expression in murine pre-B cells increased Mll1 ex-
pression through an indirect mechanism, where Bcl6 represses the ex-
pression of Bmi1, Ctbp2 and Kdm2B, which in turn are transcriptional
repressors of Mll1. This suggests that Mll1 and Bcl6 are connected
through a positive feedback loop, which appears to be conserved in
leukaemic cells [84].
3.2. Mechanisms of MLL1 function
To understand how Mll1 operates in cells, the effect of deleting its
catalytic SET domain was explored. Homozygous deletion of the Mll1
SET domain reduces H3K4me at Hox loci resulting in their misexpres-
sion [85]. Despite this, mice survive embryogenesis through to adult-
hood with only mild skeletal defects suggesting non-SET dependant
functionality. Mishra et al. utilised this model in HSPCs to demonstrate
that the loss of HMT activity is compatible with normal haematopoiesis
in adult mice and is dispensable for MLL-AF9-mediated transformation,
one of the most common MLL1 leukaemogenic oncofusions. The loss of
SET or even Mll1 in its entirety did not affect global H3K4me levels,
suggesting this histone modification is not required to maintain Mll1
target gene expression. Instead, Mll1 recruits the acetyltransferase MOF
for H4K16ac at the transcription start site (TSS) for this purpose
[54,86]. Inhibition of Sirt1, which removes H4K16Ac, recused the loss
of transcription following Mll1 deletion at Mll1 target genes, indicating
that it opposes MOF activity.
In adult mice, microarray analysis of CD48- Lin- Sca1+ Kit+ (LSK)
HSPCs 6 days following Mx1-Cre-mediated excision showed that Mll1
operates within a molecular network that extends beyond the regula-
tion of Hox genes [87]. Following deletion using both Mx1-Cre and
estrogen receptor (ER) Cre inducible knockout models, five genes,
Mecom, Prm16, Hoxa9, Pbx1 and Eya1, were identified as consistently
downregulated and found to have Mll1 bound at their TSS. Over-
expression of these targets in wild-type and Mll1−/− LSK cells showed
that no individual protein can restore normal expression levels of the
proposed network in Mll1−/− cells, with the exception of Evi1 which
increased Prdm16 and Hoxa9, thus, these proteins are likely to function
independently as downstream effectors of Mll1 function. Transplanta-
tion of Mll1−/− cells that overexpress Prdm16 and Hoxa9 showed that
these direct Mll1 targets are the most capable at rescuing the loss of
HSC function by restraining proliferation. These results showed that
Mll1 does not require its intrinsic methyltransferase activity to perform
its functions, and that MLL1 fusions can operate through distinct me-
chanisms.
4. MLL2 in haematopoiesis
Despite significant homology, germline Mll2 deletion does not
phenocopy what is seen with Mll1. In Mll2−/− embryos, earlier growth
retardation becomes increasingly apparent from E6.5 with no obvious
cell type-specific defects by E9.5, and the embryos die by E10.5 through
widespread apoptosis [88]. The maintenance of the mesodermal marker
Mox1 and Hoxb1 was dependant on Mll2. Indeed other HoxB cluster
genes were deregulated, which differs from Mll1, which mediates the
HoxA and HoxC clusters. After E10.5, Rosa26-CreERT2-mediated Mll2
loss had no effect on embryogenesis, including blood development;
however, Mll2 does play a non-redundant role in oocytes as the main
H3K4me2/3 HMT and in male and female fertility [89,90].
During adulthood, the use of a Rosa-CreERT2 model showed that
Mll2 is required to mediate proper cytokine signalling during macro-
phage function [91]. Following lipopolysaccharide (LPS) stimulation,
Mll2−/− macrophages display attenuated intracellular NF-κB signalling
because of reduced Tlr4 activation. This was a direct consequence of
Pigp loss, which functions to add glycophosphatidylinositol to trans-
membrane proteins. This caused a loss of CD14 anchoring at the cellular
membrane, which functions with Tlr4 in response to LPS. At the Pigp
gene promoter and other direct Mll2 targets, deletion led to large in-
creases in H3K27me3 suggestive of a requirement for H3K4me3 in
opposing PcG repression. Alternatively, although some did, the ma-
jority of promoters that lost H3K4me3 experienced no changes in ex-
pression, suggesting that there are loci-dependent rules that dictate the
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relationship between Mll2 HMT or transcriptional effector activity and
function.
5. MLL3 and MLL4 in haematopoiesis and blood disease
MLL3 and MLL4 are predominantly associated with the deposition
of H3K4me1 at enhancers [92–94].This functionality is consistent with
the sole Drosophila homolog Trr [24,95]. Trr loss does not result in
embryonic HOX gene misexpression as is seen with Trx (homolog of
MLL1/2), nor can Trr mutants influence Trx or PcG mutant homeotic
phenotypes [22]. Both MLL3 and MLL4 function to prime enhancers as
coactivators with the H3K27 acetyltransferases CREB-binding protein
(CBP)/p300 which are hallmarks of active enhancers, a function that is
likely independent of the SET domain [75,94,96–98]. Individually,
Mll3-null mice die shortly after birth with no obvious morphological
defects, whilst Mll4-null embryos show lethality at approximately E9.5
[94]. Corresponding to a requirement for HMT activity during embry-
ogenesis, Mll4 SET deletion causes lethality at approximately E10.5
[99]. Both perform partially redundant functions during adipogenesis
and myogenesis with Mll4 acting as the major H3K4me1/2 methyl-
transferase [94,100,101].
In the context of leukaemia, it is known that MLL3 functions as a
tumour suppressor in 7q acute myeloid leukaemia (AML), and short
hairpin RNA (shRNA) knockdown or CRISPR-Cas9-mediated deletion of
Mll3 generates a transplantable and fatal leukaemia in p53-null HSPCs
[102]. Competitive transplantation of p53-null shMLL3 HSPC increases
the frequency and number of LT-HSC, whilst decreasing downstream
multipotent progenitors (MPP), suggesting a role for Mll3 in mediating
differentiation from HSCs [102]. Concordantly, transplanted mice show
reduced white blood cell and platelet counts and a decreased con-
tribution from shMll3-targeted HSPC to common myeloid progenitor
(CMP) and granulocyte-monocyte progenitor (GMP), although not
megakaryocyte-erythrocyte (MEP). Thus, in this context Mll3 imparts a
myeloid bias and is required for progenitor differentiation.
Within the HSPC compartment, Mx1-Cre-mediated Mll4 deletion
increases overall LSK numbers that correspond to expanded LT-HSC,
MEP, CMP and myeloid (CD11b+ Gr1+) cells, but not myeloid-biased
HSCs, whilst reducing common lymphoid progenitors (CLP) and B-cell
numbers [103]. Despite increased colony counts in successive rounds of
myeloid CFU, competitive transplants using whole bone marrow or
sorted LSK showed significantly reduced reconstitution ability as com-
pared to wild-type mice. Non-competitive transplants allowed for
comparable repopulation, suggesting that Mll4 mediates the response to
stressed haematopoiesis [103]. Transcriptome profiling ofMll4−/− LSK
showed that Mll4 mediates the response to oxidative stress, and null
cells were characterised by increased reactive oxygen species (ROS) and
DNA damage confirming the functional defect. Interestingly, in HSPCs,
Mll4 deletion prior to transformation or knockdown following retro-
viral MLL-AF9 transduction prevented leukaemogenesis. Transcrip-
tional and functional testing of Mll4−/− MLL-AF9 cells showed that
increased ROS, DNA breakage and DNA-damage signalling was suffi-
cient to promote myeloid differentiation. Thus, Mll4 protects HSPCs
from DNA damage and oxidative stress, which allows for proper en-
forcement of a leukaemic differentiation blockade [103]. Abrogation of
the tumour-suppressive DNA-damage response through deletion of
genes such as Brca1, Atm and Atr are crucial to maintain the differ-
entiation block caused by MLL-AF9.
In normal B-cells, Mll4 functions non-redundantly as an MLL/SET
member that can positively influence all H3K4 methylation states, and
is notably associated with H3K4me1 at enhancers and H3K4me3 at the
promoters of genes that control B-cell signalling pathways [104,105].
Loss of Mll4 causes a proliferative advantage that expands the germinal
centre (GC), which is enhanced by CD40 and IL4 stimulation and re-
presents the cell type that is causative to diffuse large B-cell lymphomas
(DLBCL) and follicular lymphomas (FL). Indeed, MLL4 loss of function
mutations are especially prevalent in DLBCLs (30%) and FLs (90%)
[106,107]. Most are monoallelic and less commonly biallelic, and
generate a truncated MLL4 protein that is unable to methylate properly
through its SET domain [105]. Mll4 deletion induced in forming GC B-
cells (via Cγ1-Cre) or earlier B-cell progenitors (CD19-Cre) only results
in significant expansion of the GC B-cell compartment when induced in
the latter, and shows that Mll4 loss must be an early event that allows
for the necessary chromatin and transcriptional remodelling events
needed for transformation [105]. Cγ1-Cre-mediated Mll4 deletion
combined with vav promoter-driven Bcl2 expression recapitulated the
human disease phenotypes that occur in the progression from a FL to
DLBCL. Altogether, this shows that MLL4 functions as a tumour sup-
pressor in BLBCL and FL and constrains mature B-cell expansion.
6. SETD1A and SETD1B in haematopoiesis
Despite structural similarity, the mammalian orthologs of
Drosophila SET1, SETD1A and SETD1B, fulfil distinct functions during
embryogenesis [14]. Setd1a null embryos do not gastrulate following
implantation and are unable to form ESCs [108]. Setd1b loss still per-
mits the formation of the three germ layers, but severe growth re-
tardation becomes apparent at E7.5 and embryos do not survive beyond
E11.5 [108]. Correspondingly, only Setd1b loss is compatible with ESC
proliferation. Interestingly, only Setd1a knockout is causative to a
global loss of H3K4me1/2/3 in ESCs, suggesting that it is the major
MLL/SET methyltransferase.
Conditional loss of Setd1a through Mx1-Cre in bone marrow cells
caused a loss in B-cell numbers that corresponded to a block in differ-
entiation from the pro-B to pre-B stage [109]. The block in B-cell de-
velopment was correlated to losses in H3K4me3 at B-cell master reg-
ulators such as Pax5 and the IgH locus. Setd1a is also required for
erythropoiesis [110]. Cre-mediated deletion driven by transgene ex-
pression from the erythropoietin promoter reduced the numbers of
splenic erythroblasts (CD71+/Ter119+) and caused a mild anaemia.
The differentiation defect was attributed to the loss of promoter
H3K4me3 and transcription at erythroid lineage genes such as Klf1 and
Gata1, which was caused by a loss of co-location of Usf1 at promoter
loci, which may recruit Setd1a and cooperate to establish accessibility
for gene expression. How these proteins locate their targets and co-
operate in this context requires further investigation.
More recently, detailed analyses have demonstrated the impact of
Setd1a and Setd1b deletion on HSPCs during foetal and adult haema-
topoiesis [111,112]. Vav-Cre-mediated Setd1a loss during foetal de-
velopment leads to death 7 to 20 days post-birth from a significantly
depleted LSK compartment, which must have failed to establish because
of Setd1a deficiency in the first definitive HSCs that did not form or
expand sufficiently [111]. Directed differentiation of ESCs to haema-
topoietic cells is often used as a model system for embryonic haema-
topoiesis in which detailed molecular mechanisms can more easily be
dissected. Using this model system, it was demonstrated that a long
intergenic non-coding RNA recruits both Setd1a and Mll1 to the pro-
moters of the Hoxb1–6 cluster, and enhances differentiation to Flk1+
mesoderm and subsequent differentiation to haemangiogenic and
CD41+ c-Kit+ HSPCs [113]. In this study, Setd1a was the major con-
tributor to HSPC differentiation as compared to Mll1. Also, Usf1 can
recruit Setd1a to the Hoxb4 promoter for H3K4me3 deposition which
strongly enhances haematopoietic differentiation from ESCs [114].
Both studies showed that Mll1 does not affect Hoxb4 expression, which
may underlie the difference in ESC fate induction. In contrast, to the
phenotype for Setd1a deletion, Vav-Cre-specific Setd1b−/− null mice
survive to a median of 25 weeks, suggesting that it is dispensable for the
specification of a foetal haematopoietic system [112]. However,
Setd1b−/− null foetal HSPCs were not tested in any functional assays.
Two studies have explored the effect of Setd1a and Setd1b deletion
on HSPC numbers during steady-state adult haematopoiesis, by trans-
planting recipient mice with HSPCs and subsequently knocking out the
target gene following a latency period. Both ubiquitous Rosa26-
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CreERT2 and SCL-CreERT (HSC-specific) gene deletion had no effect on
LT-HSC numbers [111]; however, Setd1a-deleted HSCs showed an in-
ability to provide reconstitution in transplants and had reduced CFU
output, confirming an intrinsic defect in these cells. Furthermore, ST-
HSCs and MPPs are expanded, and significant depletion of downstream
CMP and MEPs was seen. The loss of MEP is consistent with Setd1a
regulating proper erythroid differentiation [110]. CLP and lymphoid-
primed multipotent progenitor (LMPP) numbers or lymphoid potential
in CFU following Setd1a depletion was not measured, leaving the
question of Setd1a involvement in B-cell development unanswered
[109]. Forced proliferation in secondary transplants with mixed bone
marrow chimeras causes LT-HSC and broad HSPC depletion, showing
that these cells become unable to compete with wild-type HSCs under
replicative stress [111]. Given the significantly reduced LSK numbers in
Vav-Cre Setd1a−/− mice, this may be consistent with a failure to ex-
pand definitive HSCs as opposed to a failure to form HSCs entirely.
Similar to the eventually lethal Vav-Cre-induced adult phenotype,
ubiquitous Setd1b deletion through Rosa26-Cre-ERT2 causes multi-
lineage dysplasia, loss of normal bone marrow and splenic tissue ar-
chitecture associated with thrombo- and lymphocytopenia, and varying
levels of splenomegaly from an accumulation of extramedullary gran-
ulocytes and myeloid precursors. Transplantations of cells derived from
both Setd1b knockout systems massively expanded the MPP compart-
ment in the bone marrow, likely causing the accumulation of myeloid
cells. Competitive transplantation of total bone marrow derived from
Setd1b−/− Rosa26-Cre-ERT2 showed no MPP expansion from null cells
but the LT-HSC, LMPP, and LK compartments were significantly de-
pleted and, correspondingly in the spleen, B-, T- and myeloid cell
contribution from null cells was significantly reduced [112]. This ne-
gated a role for Setd1b in maintaining MPP numbers, and allowed for
the demonstration of intrinsic Setd1b function that was masked by
compensatory stress-based mechanisms that arise during defective
haematopoiesis, imposed by a non-competitive setting.
Setd1b, in contrast, is required to maintain steady-state HSC and
progenitor populations in the adult, but is not required for foetal hae-
matopoiesis, highlighting the differences between foetal and adult
blood. Transcriptionally, the inability to sustain HSPC homeostasis is
associated with a loss of mitochondrial and metabolic associated pro-
cesses indicative of reduced cellular activity. Indeed, plating of
Setd1b−/− c-Kit+ HSPCs in myeloid-supportive CFU showed a pro-
gressive reduction in output proportional to an increase in the age of
Setd1b−/−mice, suggestive of increasing stem cell exhaustion, and they
are unable to sustain the proliferative demand imposed by MLL-ENL.
Importantly, key markers across all haematopoietic lineages such as
Mpo, Klf1 and Il7r were downregulated within HSPCs showing that
Setd1b is required to maintain the expression of blood fate and lineage
programming factors. Thus, Setd1b is intrinsically required to regulate
HSPCs in the adult blood system, where it maintains proper myeloid
and lymphoid differentiation.
Overall, both Setd1a and Setd1b are differentially required to
maintain HSPC populations, although not all compartments were
equally analysed (Table 2). Transcriptional analysis of bone marrow
derived from Rosa26-CreERT2 Setd1a−/− reconstituted chimeras
showed that LT-HSC gene signatures, and DNA damage recognition and
repair pathways were broadly downregulated [111]. Different func-
tional assays demonstrated a ROS-independent reduction in DNA da-
mage response and repair potential. H3K4me3 as shown by ChIP-qPCR
was reduced at target genes such as Fancd2 and Orc5, and in LSK, it is
the major contributor to all forms of H3K4 methylation, indicating a
direct role for H3K4 in mediating the knockout phenotype. This sug-
gests that Setd1a functions to regulate LT-HSC identity and maintains
genomic integrity especially in response to stressed haematopoiesis;
however, whether this is direct transcriptional regulation and the role
that H3K4 plays in mediating this response is unclear. In support of a
role in directly regulating a transcriptional response, a SET-independent
non-catalytic domain within SETD1A can bind Cyclin K, which
maintains a DNA damage response through CDK12/13 to ensure the
survival of MLL-AF9 AML cells [115]. Contrastingly, methylation
mediated by SETD1A is required during replicative stress to protect
replication forks by preventing RAD51 destabilisation, which protects
nascent DNA from uncontrolled resection by the helicase/nuclease
DNA-2 [116]. Ablation of H3K4 methylation allows for CHD4 locali-
sation, which promotes fork degradation and subsequent genome in-
stability. Indeed, the loss of SETD1A sensitises cells to genomic damage
in line with what was observed in SETD1A null HSPCs, although no role
could be implicated for Cyclin K in this process [111,115,116]. In ad-
dition, the ability of SETD1A-dependent methylation to control protein
localisation and interaction has been shown to regulate the cellular
localisation of YAP, which in turn promotes transcription factor asso-
ciation and downstream expression [117]. Therefore, SETD1A can
utilise different functionalities in response to different contexts.
7. Requirement of MLL/SET proteins in MLL-rearranged
leukaemia
Following MLL1 translocation, the C-terminal HMT SET domain is
lost and the N-terminal DNA-binding and protein interaction (discussed
above) domains become fused to a partner gene. Therefore, one wild-
type MLL1 allele is lost in patient blasts. In rare circumstances, the
second allele is also lost indicating a lack of selective pressure to retain
it in leukaemia [118–120]. There are mixed reports on how MLL1
contributes to MLL-rearranged leukaemia. Initially, the prevailing
thought was that MLL1 is always required [58,121,122]. Genetically
deleting MLL1 through Cre and shRNA targeting of the C-terminal wild-
type domain in primary murine or human MLL-AF9 cells impaired
leukaemic proliferation and viability which was coupled to the loss of
Ccna2 and Hoxa9 expression [121]. In mouse embryonic fibroblasts,
this was attributed to MLL-AF9 not being able to bind the Hoxa9 locus
in the absence of Mll1. Specifically, protein domain mutagenesis re-
vealed a minimal set of recruitment requirements that are fulfilled by
Mll1 through the DNA binding CXXC domain that must interact with
the PAF1 elongation complex, and the PHD3 finger domain, which is
lost in MLL1 fusions and recognises H3K4me2/3 [58]. Reintroduction
of Mll1 into null cells rescued MLL-AF9 recruitment to Hoxa9 through
pre-loading of Mll1 at the locus [58]. Small molecule inhibition of the
MLL1 and WRD5 interaction crucial for MLL1 HMT activity impaired
the growth of transformed primary murine and MLL-rearranged cell
lines, but did not impair the proliferation of normal bone marrow
progenitors in vitro [122]. This suggests that MLL1 enzymatic activity is
required for the disease, which contrasts with previous reports that
show that embryonic development, adult haematopoiesis and MLL-AF9
transformation can proceed in the absence of the SET domain [85,86].
Furthermore, conditional Mll1 deletion has demonstrated a need for
Mll1 during adult haematopoiesis [79,81,82]. In further support,
aberrantly increased expression of BCL6 correlates with increased MLL1
expression in both paediatric and adult MLL-rearranged B-cell acute
lymphoblastic leukaemia (B-ALL) and defines a specific subset of pa-
tients with poor clinical outcome [84]. Specific to this subset of B-ALL is
a dependency on BCL6, which can operate through a positive feedback
loop with MLL1 to upregulate BCL6 (discussed above) and repress the
proapoptotic BH3-only molecule BIM.
In opposition, the use of two independent conditional Mll1 knock-
outs and CRISPR-Cas9-mediated deletion showed that Mll1 loss did not
significantly affect the self-renewal, proliferation and growth of MLL-
AF9 leukaemic progenitors and generated a fatally transplantable dis-
ease with similar kinetics to control Mll1 heterozygote cells (which
show no overt phenotype) [123]. However, unlike Mll1, inducible loss
of Mll2 delays leukaemogenesis in vivo, and genetic deletion reduces
leukaemic cell proliferation and viability. Interestingly, this effect was
compounded when Mll1 and Mll2 were deleted together, indicating a
synergistic contribution to leukaemic function. Transcriptionally, Mll2
directly targets Magohb and Pigp, which were downregulated following
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Mll2 loss, with and without simultaneous Mll1 deletion [88,91,124].
This combinatorial transcriptional response following Mll1/2 loss
causes deregulation of NFκB, integrin β-3 and IL3 signalling, all major
AML survival pathways and may represent critical vulnerabilities.
Globally, Mll2 loss alone was the sole contributor to reductions in
H3K4me2/3 at its targets, indicating that Mll2 SET function can drive
leukaemic maintenance. Mechanistically, it is unclear how Mll1 co-
operates with Mll2 from this study, and despite Mll2 not maintaining
functional HSPCs during normal haematopoiesis, in MLL-rearranged
leukaemia, the context allows for differential use of these proteins once
transformation has occurred.
In HSPCs, Mll1 controls a specific transcriptional programme that is
further upregulated and essential for MLL1 fusions and includes Hoxa9,
Meis1, Eya1, Mecom, with the exception of Prdm16 [87]. As opposed to
deleting Mll1 following transformation, further work in the Ernst lab
looked at whether Mll1 deletion would impair the ability of MLL-AF9 to
initiate a leukaemia [125]. Mll1 null HSPCs were transformed by MLL-
AF9 and displayed no differences in disease latency nor CFU pro-
liferation and growth. This suggests that MLL-AF9 is able to induce the
transcriptional programme needed for transformation that is lost when
Mll1 is deleted. Only Mecom was not re-activated following MLL-AF9
induction, which suggests that MLL1 is required to prime the locus for
MLL-AF9 [125]. Thus, the catalytic C-terminus of MLL1 that is not
found in MLL1 fusions is not required for target gene activation in the
context of transformation [85,86]. Therefore, MLL1 fusions can bypass
MLL1 to activate genes for transformation, likely by aberrantly re-
cruiting transcriptional activators such as the super elongation complex
(SEC) [126].
The use of different inducible Mll1 alleles and the resulting differ-
ences in severities could be causative to the confounding results seen.
Chen et al. make a robust case with different conditional strains to show
that Mll1 is not required to maintain or initiate MLL-rearranged leu-
kaemia. Even though MLL1 fusions can bypass MLL1, it does appear
that MLL1 can prime loci (such as Mecom or Hoxa9) for subsequent
activation by MLL1 fusions. However, the requirement for endogenous
MLL1 usage as extrapolated from patient-derived data is compelling. As
demonstrated for MLL-rearranged B-ALL, such usage may reflect on this
particular subset of leukaemia and/or its human origin. Further extra-
polation from patient-derived data and subsequent validation in re-
levant systems will be crucial to confirming how this is the case. It is
unclear whether the catalytic domain of MLL1 is required in leukaemia.
As MLL2 does not play a role as broad as MLL1 in haematopoiesis,
MLL2 targets are a promising class for therapeutic investigation
[88,91].
8. The impact of MLL1 fusions on haematopoietic development
Within infants (0–1 years), 80% of all B-ALL and 50% of AML cases
are caused by MLL1 rearrangements [127]. These MLL1 fusion events
occur in utero [128–130], and within each AML or ALL subclass, pa-
tients can be sub-categorised based on the fusion type. Interestingly,
fusions such as MLL-AF9 can generate infant or paediatric B-ALL de-
spite only causing AML in adults, and may be influenced by the foetal
microenvironment, which imparts a lymphoid bias [127,131]. As age
increases, MLL1 fusions become less prevalent as a subclass and in-
creasingly require additional activating mutations, further highlighting
the distinct nature of the infant disease [132,133]. Indeed, within in-
fants, MLL1 rearrangements present with an effective 100% con-
cordance rate between monochorionic twins, who rapidly develop overt
leukaemia, suggesting that the fusion is sufficient for complete trans-
formation [128,130,134].
Responsible for approximately 50% of infant B-ALL is the MLL-AF4
fusion. These patients are a particularly high-risk sub-group that retain
very poor outcomes despite substantial improvements in paediatric ALL
[135,136]. Patient blasts are arrested during early B-cell development
at the pro-B stage (CD10 negative) and frequently co-express myeloidTa
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markers, suggesting that the transformation event is likely to occur in
an early HSPC. This disease presents with some of the lowest somatic
mutational landscapes of all sequenced cancers, they are clonal and lack
significant heterogeneity with the exception of occasional activating
mutations in RAS or FLT3, which are usually subclonal [133,137].
These patients can be further subcategorised by a lack of HOXA
expression, which is linked to worse outcomes and increased relapse
rates [138,139]. A HOXA signature correlates to significantly better
outcomes and to expression of the reciprocal fusion AF4-MLL [137].
Specific to infant MLL-AF4 patients has been the detection of the fusion
in bone marrow mesenchymal stromal cells [140]. This suggests that
the fusion arises in a prehaematopoietic precursor and that its expres-
sion in non-blood cell types within the haematopoiesis-supportive
stroma may shape the development of both the normal and leukemic
haematopoietic compartments. This would impact the first definitive
HSCs that emerge from a subset of endothelial cells known as the
haemogenic endothelium, in a process termed endothelial-to-haema-
topoietic transition (EHT) (reviewed in [141]), and especially their
further expansion and differentiation in the foetal liver.
To derive further insight into how MLL-AF4 may affect foetal hae-
matopoiesis, MLL-AF4 has been expressed in cord blood (CB)-derived
CD34+ cells and in ESCs. Indeed, viral induction of MLL-AF4 expres-
sion in human ESCs initially promotes the emergence of haema-
toendothelial precursors (CD31+ CD34+ CD45-) (HEPs), but then
skews the balance of commitment towards endothelial fate, impairing
haematopoietic output [142]. In this study, transformation was not
achieved despite the expression of canonical MLL1 fusion oncodrivers
HOXA9 and MEIS1, suggesting this is not the stage for transformation
and that the in vitro ESC system is unable to recapitulate the foetal
haematopoietic events during which transformation occurs. Upregula-
tion of genes within the HOXA (9,13) and B (2,3,4,5,6) clusters was
seen, and may play a role in regulating cell fate during the mesodermal
to haematopoietic transition, which may have a functional impact on
later leukaemia development. Furthermore, recent data from the Me-
nendez lab using human pluripotent cells, showed that expression of
both MLL-AF4 and its reciprocal fusion, AF4-MLL, strongly enhanced
the specification of haemogenic- and endothelial-primed HEPs [143].
Thus, expression of AF4-MLL balances out the endothelial bias seen
when MLL-AF4 is expressed alone, suggesting that both can cooperate
during early blood specification to modulate both endothelial and
haematopoietic cell fate. Significantly, 50% of infant MLL-AF4 patients
express AF4-MLL, which is associated with activation of the HOXA
cluster [137]. Molecularly, why this is the case is still an open question.
The current thought is that AF4-MLL can disrupt transcriptional con-
trol, in part by interacting with the SEC through AF4, and create a more
permissive environment to transcription, thereby increasing cellular
plasticity and response to treatment. [144–146].
The use of CD34+ human CB has been more instructive with re-
spect to leukaemic initiation. Initial attempts using human MLL-AF4 or
in combination with activating mutations such as KRAS or FLT3,
showed increased proliferative capacity and engraftment potential of
transduced cells, but did not generate leukaemia [147–149]. Lin et al.
showed that by replacing the human AF4 construct with the murine
equivalent, a much higher retroviral titer was produced and suggested
that human AF4 may have impeded previous studies [150]. Transduc-
tion of this hybrid in murine HSPCs generated an AML, whereas in
human CB a pro-B ALL developed that expressed myeloid markers in
xenografts. The pro-B phenotype lacked HOXA9 expression, which is
consistent with a lack of AF4-MLL expression, and expressed RUNX1,
which is correlated to poorer clinical outcome in adults [137,146].
Transduction of human CB with MLL-AF9 preferentially generated an
AML and ALL; however, the differentiation arrest occurred at the later
pre-B stage. This has been the most representative pro-B ALL model
generated thus far for MLL-AF4. Accordingly, retroviral transduction
and genetic editing of human CB with MLL-ENL and MLL-AF9 produces
ALL, AML and mixed-lineage leukaemias with the latter fusion and
entirely ALLs with MLL-ENL in xenografts, recapitulating the pheno-
types of human disease for these two fusions [151,152].
Whilst there will be conservation in the mechanisms derived from
CB or ESC towards the molecular processing that is directed when the
fusion occurs in vivo, modelling how MLL fusions impact foetal hae-
matopoiesis with relevant timing is essential to uncovering the char-
acteristics of the infant disease. Indeed, foetal HSPCs possess distinct
molecular characteristics that are the result of foetal-specific intrinsic
and extrinsic factors, and the cell of origin for the disease is known to be
a critical determinant towards the resulting pathology
[131,144,153–158]. Accordingly, identical knock-in models of adult
MLL-AF9 and MLL-ENL leukaemia have shown that disease originates
more efficiently from different HSPC populations when comparing both
fusions, and that MLL-AF9 expression in LT-HSC causes a more ag-
gressive leukaemia as compared to disease derived from GMP
[157,159]. Important for infant leukaemia is to understand the con-
tribution of developmental processes that shape the response to the
leukaemic fusion, and may be especially important for MLL-AF4 which
still displays dismal outcomes for patients. For example, the neonatal
microenvironment can potentiate AMLs generated by retroviral trans-
duction of murine HSPC with MLL-AF9 or MLL-ENL for mixed-lineage
leukaemia output [131]. Furthermore, a MLL-ENL knock-in model
showed that leukaemia initiates more efficiently from foetal and neo-
natal cells as compared to their adult counterparts, owing to younger
HSPCs being more competent at activating the required oncogenic
programme [160].
Barrett and Malouf et al. combined the use of a conditional MLL-AF4
invertor mouse with the Vav-Cre or VEC-Cre lines to target MLL-AF4
expression to the foetal blood system. The latter Cre strain targets the
haemogenic endothelium, which is the precursor to all definitive blood
[161]. Functional testing of total AGM and foetal liver-derived cells at
E11, E12 and E14 in lymphoid CFU identified a window between E12-
E14 that causes a significant increase in total B-lymphoid output
(B220+ CD19+) relative to all other timepoints during blood devel-
opment. The colonies were also visibly larger, suggesting an increased
proliferative capacity relative to controls. E11 AGM-derived HSCs were
unable to match control reconstitution levels in transplants further re-
inforcing this window. E12–14 HSCs showed the highest levels of re-
population, which were carried through to secondary transplants in-
dicating enhanced self-renewal capacity through MLL-AF4. Indeed, at
this stage the haematopoietic system undergoes substantial expansion
and differentiation, which may provide the required context that MLL
fusions can exploit during embryogenesis for leukaemia [162]. Sorting
of HSC/MPP and LMPP revealed that it was the LMPP fraction that was
the major contributor to B-lymphoid colony output, which had a pro-B
phenotype, reflecting the developmental stage of B-cell arrest in ALL
patients. Transcriptionally, MLL-AF4-expressing LMPP display higher
levels of canonical MLL fusion oncoprotein targets such as Meis1 and
Hoxa9, B-cell lineage transcription factors Ikaros and E2a, and potential
infant MLL-AF4 molecular drug targets Hmga2 and Lmo2 as compared
to MLL-AF4-expressing HSC/MPP [163]. Wild-type LMPP innately ex-
press higher levels of B-cell lineage genes Il7r and Pax5, and higher
levels of MLL-AF4 direct targets such as Bcl2 and Runx1 which are
further upregulated in LMPP following MLL-AF4 induction. Thus, LMPP
have the appropriate molecular characteristics to propagate Mll-AF4
pro-B ALL in this pre-leukaemic model, suggesting that it can act as the
cell of origin for the disease. The observed B-lymphoid bias translated
into a transplantable long-latency B-cell lymphoma not seen in infant
patients, which have an acute nature. Despite this, this model allowed
for the description of the necessary pre-leukaemic events needed to
initiate an infant MLL-AF4 B-ALL and demonstrated how MLL-AF4 ex-
pression subverts normal haematopoietic development. Certainly,
faithful models of B-ALL in mice have been difficult to generate, most
likely due to species differences in blood function, which commonly
manifest themselves through a myeloid bias and may be imposed by the
murine microenvironment.
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Recent work in human tissue has demonstrated the existence of a
foetal-specific CD10 negative PreProB-progenitor that demarcates the
first committed transition towards the B-cell lineage [164]. This pro-
genitor only displays B-lymphoid and not myeloid output in vitro that is
coupled with an upregulation of B-cell genes as it differentiates into
downstream pro-B cells; however, it retains stem cell, myeloid and T-
cell associated gene signatures, albeit at lower levels than multilineage
upstream LMPP or myeloid progenitors. At the level of chromatin,
PreProB cells retain accessibility at B-cell genes and in concordance
with RNA expression, chromatin is accessible at foetal stem cell
(LIN28B) and myeloid (MPO) genes. Interestingly, the PreProB pool
undergoes substantial proliferation from 10 post-conceptional weeks
(pcw), peaking at 11 in the foetal bone marrow and continues to be
significantly high by 21 pcw despite downstream pro-B and B-cell
progeny expansion. Thus, despite unilineage output in assays, this po-
pulation appears to have a transitionary transcriptional and chromatin
status. A high proliferative output in combination with a VDJ re-ar-
rangement (D-JH) and transcriptional status that is similar to that of
infant MLL-AF4 blasts, suggests that this CD10- PreProB progenitor
could be a cell of origin candidate for the infant disease. It will be in-
teresting to see how this committed progenitor responds to MLL-AF4,
and whether innate priming with stem cell and myeloid genes (as seen
with the LMPP) could be informative to any lineage switching me-
chanisms, which occur frequently at relapse [165,166].
9. Concluding remarks
It is increasingly clear that the MLL/SET family are essential to
foetal, adult and diseased blood function and distinctly contribute to
gene expression with cell type-specific behaviour. All commonly share a
SET domain and have homologous architecture especially in their re-
spective pairs, and yet can display distinct context-dependent functions.
Thus far, specificity for each MLL/SET is not easily explained by the
different ways that each protein can be recruited to chromatin, and it is
likely that further factors play a part [14,167]. As MLL/SET proteins
individually possess many domains and form multi-protein scaffolds for
function, this is consistent with the notion that chromatin proteins lo-
cate their targets through the combinatorial action of multivalent in-
teractions which come together to stabilise the final complex
[14,58,68,168]. One aspect that may dictate MLL/SET usage is stoi-
chiometric difference, which implies that their expression differs be-
tween developmental stages and tissue cell types [66].
Internally, small differences in domain structure are functionally
important. For example, MLL2 cannot interact with LEDGF as it lacks a
short series of 41 residues that are required to mediate a bridge be-
tween menin and LEDGF as seen with MLL1 (Fig. 2) [51]. Furthermore,
these differences manifest as differing affinities towards the WRAD
scaffold, which directly influence methylation capacity [35,36]. Pre-
existing histone H2BK120ub1 is a feature of MLL/SET and COMPASS
activation, which is also shared with the histone 3 lysine 79 methyl-
transferase DOT1L [36,41,169]. In MLL-rearranged leukaemia, aber-
rant recruitment of DOT1L by fusions also requires the action of the
ubiquitination machinery for DOT1L to access chromatin, where it
operates as an essential component of MLL fusion target gene activation
through the deposition of its gene-activating H3K79 methylation mark
[170–172]. Since DOT1L also plays a role in normal foetal and adult
haematopoiesis, further structural and biochemical studies will be
crucial to understand how all of these interactors and their cross-talk
come to coordinate MLL/SET functional capacities in health and disease
[169,173–175].
The role that these proteins play in coordinating cellular states in
HSPCs is not always coupled directly to methylation action. For ex-
ample, haematopoiesis and MLL-rearranged leukaemogenesis can pro-
ceed normally in the absence of the Mll1 SET domain, where Mll1 re-
cruits MOF for H4K16ac at target genes [54,86]. Interestingly, Mll4 also
co-locates with MOF and H4K16ac at a subset of its target sites [176].
Mechanistically, Mll4 can recognise H4K16ac via its PHD6 finger do-
main, and Mll3 via PHD7. As discussed above, SETD1A can function in
distinct contexts to directly recruit co-factors, or through methylation,
mediate protein access and activity with functional consequences.
Further work that explores domain functionality in haematopoietic
contexts will crystallise how much functionality is conserved across the
MLL/SET family and when HMT activity is applicable.
MLL/SET can control key HSPC programmes such as self-renewal
for HSC function (MLL1), the insurance of genomic integrity in pro-
liferating HSCs (SETD1A), mediation of differentiation from HSC to
downstream progenitors (MLL3) (Tables 1, 2). As discussed above,
MLL1 fusions are able to skew the balance between haematopoietic and
endothelial cell fate commitment, and both Setd1a and Mll1 have been
shown to play in role in haematopoietic specification from ESC
[113,114,177]. How MLL/SET proteins function during the establish-
ment of the haemogenic endothelium and/or early primitive haema-
topoietic progenitors remains underexplored (Table 1). Given the multi-
domain nature of MLL/SET and that foetal blood cells are distinct from
their adult counterparts, it is entirely possible that new molecular
mechanisms could be found [154,156]. As noted in Table 1, there is
much to learn about the developmental phenotypes of the MLL/SET
family.
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